Frank R. Sisto

Health Technology

Profile

Frank R.
Sisto has been Vice President of Regulatory Affairs for Mylan Laboratories, Inc. since 2003.
From 1995 to 2003, he was Executive Director, Vice President and Executive Vice President for Mylan Pharmaceuticals, Inc. He held various positions in regulatory affairs at Glaxo Inc., A.H.
Robins Co. and Bristol Laboratories.

Former positions of Frank R. Sisto

Companies	Position	End
Mylan Laboratories, Inc. Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.	General Counsel	2007-10-01

See the detail of Frank R. Sisto's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Frank R. Sisto's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Mylan Laboratories, Inc. Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.	Health Technology